Memel Biotech has announced it’s launch of a fully integrated, advanced therapy development and manufacturing service from its facility strategically located for EU markets at the Baltic seaport of Klaipeda, Lithuania.
Memel will target partnerships with both emerging and established biotech companies looking to enter the advanced therapy space. Operating from a new GMP facility, Memel will offer a seamless discovery-to-delivery service for all three classes of advanced therapies – cell, gene and tissue engineered.
Over the past two decades, the Memel team has gathered a wealth of technical experience in product formulation, process and analytical development, process scale-up and automation, GMP manufacturing, validation and logistics.
This is complemented by up-to-date knowhow of regulatory approval demands and processes in all key markets.
Memel’s manufacturing range includes Mesenchymal Stem Cells (MSCs), Induced Pluripotent Stem Cells (iPSCs), Extracellular Vesicles (EVs), Immune cells (NK, DC) and gene modified cells, including CAR-T cells.
Agnė Vaitkevičienė, CEO of Memel, explains: “Advanced therapies have enormous potential to make life changing impacts on patients, but there is no escaping the fact that they are complex and challenging to manufacture and deliver. Based on our previous experience in the sector, we believe Memel has the portfolio of services and skills to meet the challenges companies that are aiming to make a difference face – from initial formulation to scale-up - whilst conforming to the still emerging regulatory framework. In addition to European clients, our location also offers an ideal EU entry point to US and ROW companies.”
